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ABSTRACT: The availability of suitable diverse fragment- and lead-oriented screening 
compounds is key for the identification of suitable chemical start points for drug 
discovery programs. The physicochemical properties of molecules are critical in 
determining the success of small molecules in clinical development, yet reports suggest 
that pharmaceutical and academic sectors often produce molecules with poor drug-like 
properties. We present a platform to design novel, high quality and diverse fragment 
and lead-oriented libraries with appropriate physicochemical properties in a cost-
efficient manner. This approach has the potential to assist the way libraries are 
constructed by significantly addressing the historical uneven exploration of chemical 
space for drug discovery. Additionally, this platform can teach both undergraduates 
and graduates compound library design. 
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INTRODUCTION  
Fragment-based drug discovery (FBDD) and high throughput screening are 
important approaches to find chemical start points for drug discovery programmes. 
These libraries rely on synthesis as well as commercial acquisition of new compounds. 
The majority of this extensive effort, mainly carried out over the last 10-15 years, 
remains unpublished, as novel proprietary compounds provide a competitive edge for 
the respective pharmaceutical companies. Hence, there is no full understanding of the 
proportion of chemical space [1,2] covered by current compound libraries and screened 
in biological assays. It is estimated that there are more than 1060 possible organic 
compounds that fulfill Lipinski’s rules [1,3]. However, a framework analysis of the CAS 
Registry suggests that chemists are more likely to use a particular framework to make a 
compound, the more often that framework has been used in the past [4]. This results in 
the proliferation of certain frameworks and limits the exploration of novel chemical 
space.  
Bemis and Murcko analyzed drug molecules according to ring, linker, framework 
and side chain atoms so that the information could be employed for the synthesis of 
new scaffolds with biological rationale [5,6]. Their analysis suggests that the scaffold 
and side chain diversity associated with known drugs is relatively low. More recently, 
analysis of  drug space (until end of 2012) by Taylor et al., describing the rings and 
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molecular scaffolds [7], showed that there were only 351 ring systems and 1197 
frameworks. Further, only six new ring systems enter drug space each year and 28% of 
new drugs contain a new ring system. This is a relatively small number compared, for 
example, to the predicted number of small aromatic rings [8]. Increasing the diversity 
and novelty of compound libraries is likely to be important in probing the drug-like 
chemical space that addresses biological space [2], to tackle both existing and emerging 
drug targets (for example protein-protein interactions).   
For many drug discovery organizations, particularly small- and medium-sized 
enterprises (SMEs) and the public sector, access to chemical matter is largely reliant on 
commercially available fragment and lead-like libraries. However, a recent analysis has 
suggested that “existing synthetic methodology is unintentionally predisposed to 
producing molecules with poorer drug-like properties and that this is likely to have 
ramifications to the early hit- and lead-finding phases of the drug discovery process” 
[9], particularly in addressing emerging target classes. In contrast, academic synthetic 
chemists are developing new synthetic methodology, which would be a powerful way 
to increase the novelty and diversity of our chemical libraries, if leveraged for 
compound library synthesis. This could be particularly beneficial for SMEs and academic 
drug discovery groups, as well as the pharmaceutical industry (Figure 1) [10].  
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Fragment-based drug discovery (FBDD) is an important approach to identify new 
leads for drug discovery [11-14]. It has the advantage of being able to address an area 
of chemical space with many fewer compounds than conventional lead-like or drug-like 
libraries. During an attempt to increase the chemical diversity of our fragment library, 
we realized that relatively simple derivatization (“capping”) of commercially available 
building blocks could expand into new areas of chemical space that are not 
commercially available, often with very different chemical and physicochemical 
properties (Figure 2), [15]. These compounds could subsequently be rapidly expanded 
into lead-like space for hits, using the same or similar chemistry. We therefore decided 
to establish a platform to design and generate compounds to address a wider range of 
fragment-space. This platform encompasses a set of criteria for compound design, and 
procedures for compound preparation and carrying out quality assurance. 
FBDD typically uses structural knowledge for fragment optimization using a range 
of strategies including merging, linking or growing [12]. Fragments typically bind to “hot 
spots” within the ligand binding site of the target [16] and options for optimization are 
prioritized according to synthetic appeal, opportunity to access relevant areas of the 
binding site, binding affinity and ligand efficiency. The prioritized fragments are then 
typically elaborated through addition of a suitable functional group, or “chemical 
handle”, to attach and elaborate the new substituent to identify further interactions 
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[11]. Ideally the chemical handle provides additional interactions within the target to 
improve affinity as well aid both fragment growth and linking.  
Screening fragments with “built-in” handles has the potential for additional 
interactions with the target (protein) and faster elaboration of a fragment. However 
care has to be taken as increasing complexity in a fragment decreases the probability of 
it achieving optimal ligand - protein interactions [17]. Conversely, too little complexity 
can lead to interesting interactions being missed [18]. Therefore, a careful balance is 
required between the “built-in” handles and the complexity of the fragment. 
Subsequent introduction of a chemical handle to a fragment may alter the binding 
conformation. This was demonstrated by Shoichet et al., who showed that 
deconstruction of a larger potent β-lactamase inhibitor into small fragments with 
“minimal complexity” does not necessarily recapitulate its binding to the enzyme [19]. 
However, fragments with additional functional-group complexity could recapitulate the 
larger potent β-lactamases inhibitor binding. Conversely, smaller fragments could 
identify more ligand efficient binding modes to the “hot spot”, which after alternative 
optimization strategies, could potentially lead to development of compounds with 
better drug-like properties e.g. lower molecular weight. 
A case study in support of the use of fragments with pendent functional groups 
suitable for rapid elaboration comes from Nazaré et al. [20] who demonstrated the 
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super-additivity effect of linking two fragments (derived from deconstructing a potent 
factor Xa inhibitor) containing amide and sulfonamide functional groups respectively 
(Figure 3).   
To make maximum use of the fragment library, an ideal scenario would be to have 
a linkage between the scaffolds in a fragment library and a lead-like library. This would 
have two advantages: firstly, a hit in a fragment screen could be rapidly expanded into 
lead-like space using analogues of the scaffold in the lead-like library, or using known 
robust chemistry to grow the fragments. Secondly, if there is a hit on screening a lead-
like library, this could be rapidly “de-constructed” into fragments to probe the key 
receptor-ligand interactions. Given the rapid increase in the number of possible 
compounds as the heavy atom count in a molecule increases, there will be a limit to the 
examples of a fragment-scaffold that can be in a lead-like library. Therefore, it will be 
important to have chemistry suitable for fragment-scaffold elaboration. 
 
RESULTS AND DISCUSSION 
Design Process. A key component of our library platform was to identify under-
represented areas of commercial chemical space and create diversity based on 
functional group manipulation. A library design team, composed of experienced 
medicinal chemists, investigated a number of procedures for synthesis of fragments 
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with differing synthetic complexity, based on the analysis of fragment scaffolds in 
relation to published biologically relevant data. Our workflow is shown in Figure 4. 
We had three start points to develop novel fragments (Figure 5): (1) in-house 
assembly of diverse monomer (appendage) sets, which could be functionalized into 
both fragment and lead-like libraries, (2) commercial and in-house project 
intermediates, and (3) novel chemical scaffolds. Designs were filtered to ensure that 
compounds selected for synthesis filled in “gaps” in chemical space in our current 
fragment library.  
Our focus here was on producing fragment and lead-like libraries to identify non-
covalent, reversible inhibitors. Functional groups known to be chemically reactive or 
toxic were removed (so called “Structural Alerts”), as were compounds reported to be 
pan assay interference compounds (PAINS) [21]. Supporting information includes the 
Drug Discovery Unit revised in-house [22] and modified Eli Lilly-published [23] 
structural alerts and the PAINS alerts. After applying the structural alerts, we then set 
about defining descriptors and selection criteria for non-covalent reversible fragment 
libraries, monomer sets and lead-like libraries (Table 1). We report the final version we 
now use, which is the result of several rounds of iteration and optimization of the 
library selection parameters; so several of the early libraries were designed with slightly 
different criteria.  
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Although a number of key reports have evaluated the impact of aromatic ring 
count [24-26] and Fsp3 on solubility and compound developability within drug-like 
chemical space [27,28], in practice, we did not explicitly factor in the aromatic ring 
count, as the other parameters took care of this. As historical fragment libraries 
(including our own) sample limited shape diversity [15], which in practice may impact 
opportunities to introduce shape diversity [29], we introduced routine calculations of 
the principal moments of inertia (PMI). Computational tools of evaluating novelty and 
diversity included ECFP4 fingerprint analysis, principal component analysis (PCA) and 
commercial availability versus established libraries (see Table 1). 
Monomer Set Selection. Diverse monomer appendage sets were compiled to 
support our early hit- and lead-finding phases. The process for diverse monomer 
appendage set selection and purchase has evolved with the selection of each monomer 
set and was often dovetailed to the availability from the internal inventory. For 
example, selection of approximately 60 diverse primary and secondary amines included 
the following: 
1. Extracting amines from the eMolecules database, salt stripping and filtering based 
on commercial availability from a set of suppliers (Aldrich, Enamine, Fluorochem, 
Tyger, Acros, Chembridge, Key Organics, ChemDiv, Otava and Maybridge, Combi-
Blocks and Frontier) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
10 
 
2. Filtering compounds based on the properties described in Table 1 for monomer 
sets, which included in-house curated structural alerts. 
3. Clustering of the filtered compounds using the ECFP4 fingerprint and binning by 
molecular weight for visual selection by a focused group of experienced medicinal 
chemists. 
4. Purposely skewing the selection towards the lower molecular weight range within 
each cluster, to provide a greater diversity of cores of varying molecular weight and 
physicochemical properties. 
5. A final set selection by further splitting into bins to ensure maximal coverage of 
both fragment and lead-like chemical space: 30 monomers were selected with MW 
≤ 120, 20 with 120 < MW < 160 and 10 with 160 < MW ≤ 200. 
 
We selected subsequent monomer sets in a similar manner and have thus far 
included carboxylic acids, sulfonyl chlorides and aldehydes. Learning from initial 
experience resulted in the monomers being enumerated after the initial filtering of the 
eMolecules search to afford the capped products and then examples taken from each 
cluster by chemist’s eye selection. Cost, commercial availability and specific project 
requirements were factored into the final design of monomer sets. 
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Monomer Set Capping Fragment Library Design. Since the monomer sets were 
diverse, as defined by fingerprint analysis and visual inspection, we considered that 
“minimal functional group transformation” would give a diverse selection of functional 
group containing fragments (see Figure 6). Based on the case study by Nazaré et al., 
[20] the initial project focused on acetylation and mesylation of the amine monomer 
set and relevant inventory amines (see Scheme 1). 
We employed the following protocol to identify the most suitable fragments for 
synthesis and selected examples of the acetylated and mesylated amine monomer set 
are shown in Charts 1 and 2: 
1. Enumeration to give the acetylated and mesylated products. 
2. The virtual products were filtered according to the fragment properties in Table 1. 
3. Structural alert filters (PAINS, Eli Lilly and in-house) were applied [21-23]. 
4. Filtered compounds were clustered using the ECFP4 fingerprint (0.5 Tanimoto). 
5. Commercial availability of the exact compound within the eMolecules database 
was checked. In general, we avoided re-making commercially available 
compounds. However sometimes when the compound was part of an array, it was 
cost-effective to include it. 
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6. Tanimoto similarity of each compound to the current fragment library was 
calculated; however this was treated as a guide and all structures were inspected 
by a medicinal chemist before preparation.  
7. PCA (ECFP4) and PMI plots were generated for enumerated products to better 
understand the chemical diversity.  
 
In our platform, designed compounds were synthesized through in-house 
chemistry or through outsourcing. The fragment functional group capping initiative, as 
part of an academic-based drug discovery unit, provided an excellent opportunity to 
nurture undergraduate students on how to design and synthesize fragments. 
Undergraduate project students were paired with a mentor and provided with a set of 
enumerated fragments for a particular monomer set coupling reaction. Guiding of 
students by the mentor through the selection process, provided valuable training in the 
use of modern in silico prediction (StarDrop™ (www.optibrium.com)) and visualization 
(Vortex) software. The reagent sets were then selected and the students guided to 
identify robust and safe synthetic routes for parallel synthesis. The optimal synthetic 
route was identified with a trial set of compounds and the library was then prepared 
using parallel techniques, starting with 6 compounds and progressing towards 24 
compound arrays. As well as using the monomer sets, this approach was extended to 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
commercially available building blocks and appropriate in-house project intermediates. 
This platform also has the advantage from a training context of being tunable, ranging 
from straightforward functional group interconversion to more complex scaffold 
synthesis. 
We extended the approach to a number of other types of chemistry, including 
urea formation (Figure 6) and cross-coupling of the monomer sets. This was rolled out 
initially to final (fourth) year project students, working in our laboratories and then 
subsequently to third year undergraduate students. The students gained a significant 
training in the parallel synthesis and purification of small polar compounds and 
excitement stimulated by production of novel compounds. 
 
Synthesis of Multiple Diverse Scaffolds from Common Intermediates. The next 
step was to identify flexible platforms for the synthesis of multiple unexplored diverse 
fragment scaffolds from readily available key intermediates. A pilot platform was based 
around the evaluation of fused bicyclic fragment frameworks described by Bemis and 
Murcko [5,6], in particular 6,5- and 6,6-fused bicyclic scaffolds, with the requirements 
of a saturated ring and sp3 vectors with diverse functional groups capable of forming 
varied pharmacophoric points. To better understand the existing landscape for such 
scaffolds, we conducted database searches and refined the output based on 
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commercial availability as well as property selection filters based on our guide criteria 
for fragment selection within Table 1. A selection of the output in Figure 7 shows an 
uneven distribution of the explored potential chemical space for a selected set of 
different vectors as well as decreased representation because of increased structural 
complexity through the addition of chirality and heteroatoms into the saturated six-
membered ring. From the authors’ experience, the fact that a compound is offered 
commercially does not necessarily mean it is readily available at a suitable cost, as 
compound suppliers often assign a synthesis time based on literature routes and a 
minimum scale. In our opinion, the output in Figure 7 provides a balanced approach for 
identifying compounds that may be available and are likely to be accessed via literature 
synthetic routes. 
To sample wide chemical space, we opted to identify common intermediates that 
could be prepared on a large scale and readily expanded into multiple structurally 
complex and diverse unexplored scaffolds. This approach led us to evaluate cyclic 
ketone building blocks, based on validated literature chemistry to make 
tetrahydroquinazoline, tetrahydroindazole and tetrahydrobenzothiazole 6,5- and 6,6-
fused bicyclic scaffold derivatives. These derivatives were targeted from three simple 
commercially available ketone starting materials, ethyl 4-oxocyclohexanecarboxylate 
(21: X = CH2CO2Et), N-Boc-4-piperidone (22: X = NBoc), and N-4-Boc-
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aminocyclohexanone (23: X = CHNHBoc), which were subsequently converted into 
diverse fused ring systems using divergent synthetic protocols (Scheme 2). These 
included α-substitution with N,N-dimethylformamide dimethyl acetal (DMF–DMA) to 
provide the corresponding enones 24–26 (24: X = CHCO2Et, 25: X = NBoc, and 26: X = 
CHNHBoc) and α-monobromination with Br2 to afford α-bromo ketones 27–29 (27: X = 
CHCO2Et, 28: X = NBoc, and 29: X = CHNHBoc). 
Acid-catalyzed cyclization of enone 24 with S-methylisothiourea afforded the 2-
(methylthio)-tetrahydroquinazoline 30, which was subsequently oxidized with m-
chloroperoxybenzoic acid (m-CPBA) to the corresponding sulfone 31. The reactive 2-
(methylsulfonyl) group of 31 was treated with ammonia, dimethylamine, and 
methylamine to access amines 32 (R1 = R2 = H), 33 (R1 = R2 = Me), and 34 (R1 = Me, R2 = 
H) respectively. 
Cyclization of enones 25 and 26 with the appropriate guanidine salts (Scheme 2), 
guanidine carbonate, 1,1-dimethylguanidine sulfate, methylguanidine hydrochloride 
provided a corresponding set of minimal amino-derived fragments 35 (X = NBoc, R1 = R2 
= H), 36 (X = CHNBoc, R1 = R2 = H), 37 (X = NBoc, R1 = R2 = Me), 38 (X = CHNBoc, R1 = R2 = 
Me), 39 (X = NBoc, R1 = Me, R2 = H), and 40 (X = CHNBoc, R1 = Me, R2 = H). Treatment of 
enones 24–26 with hydrazine hydrate afforded indazoles 41–43 (41: X = CHCO2Et, 42: X 
= NBoc, and 43: X = CHNHBoc), whereas coupling of α-bromo ketones 27–29 with 
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thioacetamide led to thiazoles 44–46 (44: X = CHCO2Et, 45: X = NBoc, and 46: X = 
CHNHBoc) (Scheme 2). Further reactions from these common intermediates could also 
be envisaged, such as reaction of enones 24–26 with hydroxylamine, cycloaddition 
reactions of the enones 24–26, or Robinson annulation of 21–23, followed by 
subsequent chemistry or building diverse ring systems from the ketone intermediates 
21–29 (Scheme 2).  
However for this study, having created a platform of diverse scaffolds, we next 
turned our attention on how to best represent potential larger lead-like arrays, by 
increasing functional group diversity and applying “capping” chemistry to generate 
more diverse fragments or to move them into lead-like space. To further diversify the 
functional groups of the 15 scaffolds in a parallel fashion, esters 32–34, 41, and 44 were 
reduced using lithium aluminium hydride to afford the corresponding alcohols 47–51 or 
hydrolyzed with NaOH to give acids 52–56. Acids 53, 54, and 56 were further coupled 
with methylamine or dimethylamine to afford the primary methyl amides 57–59, or the 
corresponding secondary dimethyl amides 60–62 respectively (see Scheme 3). 
Further examples are included in the Supporting Information. Of course many 
other derivatizations can be applied to the scaffolds in Scheme 3, such as reductive 
amination, ether formation, conversion of the carboxylate to a five-membered 
heterocycle, and so forth. 
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The above functional group modifications provided a more even sampling of 
potential pharmacophores for these 6,5- and 6,6-fused bicyclic scaffolds. These initial 
scaffolds are limited to a specific vector; however, we envisage that the methodology 
can be extended to different vectors, saturated ring sizes as well as further addition of 
heteroatoms into the saturated ring system. 
Evaluation of the Compounds. PCA (ECFP4) analysis of these diverse fragments 
showed that they were significantly different from the historical fragment library 
(Figure 8a). This was considered largely to be as a result of the synthetic design to 
incorporate a heteroaromatic ring fused to a sp3-saturated ring with a chiral vector of 
varied functional groups. PMI analysis was used to evaluate the 3D diversity of the 
fragments, due their relatively limited numbers of conformations due to their small size 
(Figure 8b) [30]. These fragments do not probe the more sphere-like region of the PMI 
plot, as the vectors explored provided a degree of rod- and disc-shaped character, but it 
is key to emphasize that these fragments are not flat and highly conjugated due to their 
design strategy (Figure 8c). To ensure that the new fragments were distinct from our 
historical fragment library, an ECFP4 fingerprint with a Tanimoto cutoff ≤ 0.6 was 
generally employed, although some compounds with higher Tanimoto similarity were 
included following visual analysis. Commercial availability (i.e., novelty) was determined 
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by searching eMolecules (Figure 8f); revealing that many compounds were not 
commercially available, enabling exploration of novel fragment chemical space. 
Evaluation of the commercial availability, shape and diversity for a range of the 
fragment sets synthesized to date are shown below, together with highlights of selected 
molecules (Figure 9). 
Plating, Quality Control, Solubility, and Stability. Compound quality and handling 
are key to the successful deployment of any screening library. This is particularly true in 
the area of fragment-based lead discovery where fragments may be routinely screened 
at concentrations up to 1 mM. When screening at such a high concentrations small 
amounts of impurity, can have a significant impact on the false positive rate and can 
lead to the wasteful deployment of valuable resources. To minimize wasted time and 
effort spent on following up artifacts, we established the following practices for quality 
control and compound handling. 
Upon synthesis, fragments were routinely analyzed from solid by 1H NMR and LC–
MS to confirm identity and ensure appropriate purity (> 95%) before registration in our 
compound management database. At this point the weighed sample was submitted to 
our compound-handling group and the data captured in the database used to drive 
solubilization protocols for preparation of stock solutions and samples for further 
characterization. Further characterization involved the collection and analysis of one-
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dimensional NMR spectra of an approximately 2 mM solution of the compound in 
phosphate buffer with suppression of the water signal by excitation sculpting [31]. 
Analysis of this data allowed further confirmation of identity, purity (> 95%) and 
allowed us to generate an estimate of solubility based on a comparison of the intensity 
of the compound signal with the DMSO-d5 peak. Water–LOGSY was also acquired for 
each compound to assess the levels of self-aggregation [32]. Further physicochemical 
characterization included kinetic solubility, by assesses the compound solubility in the 
range of 250 µM to 1 mM, and CHI logD (pH7.4) data on selected fragment. As 
expected, based on the in silico design predictions, the kinetic solubility was overall 
very good for the majority of the compounds, with only a handful with kinetic solubility 
between 250 µM to 1 mM (Figure 10a). Since fragment and lead optimization based 
drug discovery programs commonly use ligand efficiency metrics based on in silico 
predictions of logP and logD, we also obtain a good understanding of the correlation 
between measured and in silico predicted values for a scaffold at an early stage. The 
coefficient of determination (R2) for a plot of the in silico predicted logD (Stardrop™) 
versus measured CHI-logD (pH7.4)[33] for fragments with a suitable chromophore, 
showed a moderate correlation (Figure 10b) [34]. This data is helpful when making 
choices between fragment hits and facilitates better in-house CHI-logD predictions for 
hit expansion and lead orientated synthesis.  
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To ensure that compound quality is maintained throughout the lifetime of the 
library, a strict compound-handling regime has been implemented. Fragments are 
solubilized and held as a 200 mM DMSO solution in master plates. These master plates 
are used to create multiple daughter plates that are sealed and stored in low-humidity, 
inert atmosphere at –20 °C until required. Once in use, each daughter set is stored at 
room temperature and used for a maximum of six months. This important part of our 
compound management workflow minimizes the significant degradation that may be 
encountered when subjecting screening sets to multiple freeze–thaw cycles [35]. An 
important part of any fragment screening protocol would be confirmation of activity 
with fresh material that has been properly checked for identity and purity. 
 
CONCLUSION 
A successful academic-based platform has been set up to nurture both 
undergraduates and graduates to understand the importance of physicochemical 
properties in the design and synthesis of novel polar fragments. This powerful, yet 
general design and synthesis platform provides a much needed source of novel high-
quality diverse fragments to complement our internal library enhancement efforts. To 
date this platform has delivered 356 diverse compounds within our selected criteria. 
Screening of these compounds has already led to the identification of fragment hits and 
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the results will be presented at a future date. We intend to apply the lessons learned 
from current and future screens to feedback into the design and selection process. As 
such, we continue to expand our platforms to synthesize diverse scaffolds from 
common bulk intermediates, develop diverse monomer sets to support internal drug 
discovery programs as well as generate novel fragment and lead-like arrays through the 
training of undergraduates and graduates. Expansion of such platforms within the 
academic sector could significantly address the historical uneven exploration of 
chemical space and improve access to high quality and diverse fragment and lead-like 
chemical matter. Such an effort should significantly improve the probability of success 
for both academic- and industrial-based translational research and we are open to 
collaborate with parties interested in adopting or supporting such platforms. Whilst 
preparing this manuscript, we were encouraged to see the recent publication of a 
conceptually similar approach by Marsden et. al. towards the synthesis of diverse 
scaffolds that can be elaborated into novel lead-like chemical space [36]. 
 
Notes  
The authors declare a collaboration with Key Organics (http://www.keyorganics.net/) to 
make fragments (which have passed the plating, quality control, solubility and stability 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
 
criteria) available for purchase, with the view of investing proceeds into additional 
design and synthesis platforms. 
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Figure 1. The importance of synthetic methodology to provide fragment, lead-like 
and drug-oriented libraries to initiate and drive translational drug discovery.  
Figure 2. The effect of “capping” a carboxylic acid can give rise to a number of 
different pharmacophores.  
Figure 3. Nazaré et al.[20] case study showing the superadditive effect of linking 
amide and sulfonamide functionalized fragments to afford a potent factor Xa inhibitor. 
Figure 4. Typical workflow. The precise order of steps was sometimes varied. 
Figure 5. Strategy for compiling fragment and lead-like libraries. 
Figure 6. Example monomer sets and minimal functional group transformations. 
Figure 7. Database substructure searches for selected 6,5- and 6,6-fused bicyclic 
scaffolds with a functional group, based on commercial availability as well as property 
selection filter (MW ≤ 250, LogP ≤ 2.5, HBD ≤ 3, HBA ≤ 6, PSA ≤ 90 Å, RotB ≤ 3).  
Figure 8. (a) PCA of synthesized diverse scaffolds (green) vs original fragment 
library (grey). (b) PMI plot of synthesized diverse scaffolds (green) vs original fragment 
library (grey). (c) Fsp3 of synthesized diverse scaffolds. (d) Intralibrary Tanimoto 
similarity of synthesized diverse scaffolds using the ECFP4 fingerprint. (e) Fsp3 of 
original fragment library. (f) Commercial availability of synthesized diverse scaffolds 
(eMolecules). 
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Figure 9. (a) PCA of capped monomer sets (green) vs original fragment library 
(grey). (b) PMI plot of capped monomer sets (green) vs original fragment library (grey). 
(c) Fsp3 of capped monomer sets. (d) Intralibrary Tanimoto similarity of capped 
monomer sets using the ECFP4 fingerprint. (e) Fsp3 of original fragment library. (f) 
Commercial availability of synthesized capped monomer sets (eMolecules).  
Figure 10. (a) Kinetic solubility versus in silico predicted logD. (b) in silico predicted 
logD versus measured CHI-logD (pH7.4), showing the line of unity.  
Scheme 1. Acetylation and mesylation of the amine monomer set and inventory 
amines: Reagents and conditions: (a) CH3COCl, DIPEA, DCM, rt; (b) CH3SO2Cl, DIPEA, 
DCM, rt. 
Scheme 2. Synthesis of 6,5- and 6,6-fused bicyclic scaffold derivatives. Reagents 
and conditions: (a) DMF–DMA, Et3N, microwave irradiation at 130 °C for 24, or DMF–
DMA, toluene, 100 °C for 25 and 26; (b) Br2, AlCl3, MeCN (27) or EtOAc (28 and 29), 0 °C 
Æ rt; (c) S-methylisothiourea, 4 M dioxane HCl solution, DMSO, 130 °C; (d) m-CPBA, 
DCM, rt; (e) 33% aqueous NH3 solution, dioxane, microwave irradiation at 160 °C for 32, 
or dimethylamine and methylamine, THF, microwave irradiation at 160 °C for 33 and 34; 
(f) guanidine carbonate, KOAc, EtOH, microwave irradiation at 100 °C for 35 and 36, or 
1,1-dimethylguanidine sulfate, and methylguanidine hydrochloride, Cs2CO3, DMSO, 80 
°C for 37–40; (g) NH2NH2, H2O, EtOH, 40 °C (41), or rt (42 and 43); (h) thioacetamide, 
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DMF, 80 °C for 44, or thioacetamide, EtOH, microwave irradiation at 100 °C for 45 and 
46. 
Scheme 3. Capping chemistry to increase diversity. Reagents and conditions: (a) 
LiAlH4, THF, rt; (b) NaOH, MeOH, reflux; (c) methylamine (57–59) or dimethylamine (60–
61), DIPEA, PPA, DCM, rt; (d) TFA, DCM, rt; (e) CH3COCl (64 and 67) or CH3SO2Cl (65 and 
68), DIPEA, DCM, rt. 
Chart 1. Selected fragments from acetylation of the amine monomer set 
Chart 2. Selected fragments from mesylation of amine monomer set 
Table 1. Descriptors and guide selection criteria employed for non-covalent reversible 
fragment libraries, monomer sets and lead-like libraries 
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Click here to download high resolution image
e-component
Click here to download e-component: Supporting Information.pdf
e-component
Click here to download e-component: DDU_structural_alerts_DDT.sdf
e-component
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e-component
Click here to download e-component: Pains_structural_alerts_v2_DDT.sdf
Table 1. Descriptors and guide selection criteria employed for non-covalent reversible 
fragment libraries, monomer sets and lead-like libraries 
Fragment  
library 
Monomer sets 
Lead-like  
library 
HAC 5–18 
LogP ≤ 2.5 
LogD ≤ 2.5 
HBD ≤ 3 
HBA ≤ 6 
PSA ≤ 90 Å 
RotB ≤ 3 
Ar rings ≤ 3 
MW ≤ 200 
LogP ≤ 2 
HBD ≤ 3 
RotB ≤ 3 
Ar rings ≤ 3 
 
HAC 14–26 
LogP –1 to 3 
Ar rings ≤ 3 
 
Commercial availability, shape & diversity 
eMolecules 
sp3 Content 
PMI (used for fragment library to impart understanding of shape where rotatable 
bonds ≤ 3) 
PCA (ECFP4) 
ECFP4 fingerprint 
Medicinal chemists eye (Vortex) 
Structural alerts 
PAINS, Eli Lilly and DDU integrated set 
Physicochemical data were calculated using StarDrop™ (www.optibrium.com). clogD values were 
calculated at pH 7.4 
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